Payments to Healthcare Professionals
Collaboration between the pharmaceutical industry and Healthcare Professionals (HCPs) or Healthcare Organizations (HCOs) benefits patients. It is a relationship that has delivered numerous break-through medicines and changed the way many diseases impact patients’ lives. Our work together includes a range of activities from clinical research to sharing best clinical practice. As an industry we make payments or ‘transfers of value’ to Healthcare Professionals and Organizations to compensate them for the time spent working with us.
Bringing greater transparency to this already well-regulated relationship builds understanding of this collaboration and addresses public concerns about interactions between the medical community and the pharmaceutical industry. We believe that openly communicating payments helps foster trust with patients, Healthcare Professionals, government officials and the public, and supports our overall commitment to data transparency and high ethical business standards. Novartis has long been dedicated to improving clinical trial data transparency and discloses relationships with patient organizations.
In several countries, we publish payments to Healthcare Professionals and Organizations in line with local laws or regulations.
About our Reporting Practices
Europe
Across Europe, Novartis discloses annually payments and other transfers of value in line with the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code and its local transpositions. The EFPIA Disclosure Code 2020 Self Certification Letter (PDF 0.5 MB) signed by Susanne Schaffert, President Novartis Oncology, confirms the application of the principles of the EFPIA Disclosure Code. The letter from previous year is available here.
Novartis also complies with the Medicines for Europe (European Generic and Biosimilar Medicines Association) Transparency Rules and Requirements, which defines disclosure rules for the generic, biosimilar and value added medicines industry.
United States
Novartis Pharmaceuticals Corporation (NPC) is required each year to submit data to the Centers for Medicare and Medicaid Services (CMS) Open Payments program (commonly known as the Sunshine Act) as an applicable manufacturer. CMS collects information about certain payments and other transfers of value from applicable manufacturers and group purchasing organizations (GPOs) to physicians and teaching hospitals. Open Payments is the federally run transparency program that collects information about these financial relationships and makes it available to the public annually through the CMS Open Payments website.
Read more about our Payments to Healthcare Professionals in the United States.
Australia, Canada, Israel and Japan
In addition to the EFPIA countries and the United States, we publicly disclose payments and transfers of value in Australia, Brazil (Minas Gerais), Canada, Israel and Japan, in accordance with local requirements.
All Disclosure Reports
Disclosure Report
Disclosure Report
Below is the disclosure information for Bosnia and Herzegovina in English as per EFPIA regulations. In case of questions please contact us.
2019
Disclosure Report
Disclosure Report
Disclosure Report
Sukladno pravilima EFPIA udruženja niže su navedeni podaci na hrvatskom jeziku za objavu za Hrvatsku. U slučaju pitanja molimo Vas da nas kontaktirate.
2019
-
Novartis
Disclosure Report (PDF 0.2 MB) Methodological Note (PDF 0.6 MB)
-
Sandoz
Disclosure Report (PDF 0.7 MB) Methodological Note (PDF 0.6 MB)
2018
-
Novartis
Disclosure Report (PDF 0.3 MB) Methodological Note (PDF 0.6 MB)
-
Alcon
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.6 MB)
-
Sandoz
Disclosure Report (PDF 0.3 MB) Methodological Note (PDF 0.6 MB)
2017
Below is the disclosure information for Cyprus in English as per EFPIA regulations. In case of questions please contact us.
2019
-
Novartis
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.2 MB)
-
Sandoz
2018
-
Novartis
Disclosure Report (PDF 0.2 MB) Methodological Note (PDF 0.6 MB)
-
Sandoz
2017
Disclosure Report
Allpool on ära toodud informatsioon eesti keeles seoses avalikustmisega Eestis vastavalt EFPIA regulatsioonidele. Küsimuste korral võtke meiega ühendust.
2019
-
Novartis
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.5 MB)
-
Sandoz
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.2 MB)
2018
-
Novartis
Disclosure Report (PDF 0.2 MB) Methodological Note (PDF 0.6 MB)
-
Alcon
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.2 MB)
-
Sandoz
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.2 MB)
2017
Disclosure Report
Disclosure Report
Disclosure Report
Disclosure Report
Disclosure Report
Disclosure Report
Disclosure Report
Zemāk ir izpaužamā informācija par Latviju latviešu valodā saskaņā ar EFPIA noteikumiem. Jautājumu gadījumā lūdzu sazinieties ar mums.
2019
-
Novartis
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.5 MB)
-
Sandoz
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.2 MB)
2018
-
Novartis
Disclosure Report (PDF 0.3 MB) Methodological Note (PDF 0.2 MB)
-
Alcon
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.7 MB)
-
Sandoz
Disclosure Report (PDF 0.2 MB) Methodological Note (PDF 0.2 MB)
2017
Žemiau rasite atskleidimo informaciją lietuvių kalba pagal EFPIA reglamentą. Esant klausimams, prašome kreiptis į mus.
2019
-
Novartis
Disclosure Report (PDF 0.2 MB) Methodological Note (PDF 0.5 MB)
-
Sandoz
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.2 MB)
2018
-
Novartis
Disclosure Report (PDF 0.3 MB) Methodological Note (PDF 0.6 MB)
-
Alcon
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.7 MB)
-
Sandoz
Disclosure Report (PDF 0.3 MB)Methodological Note (PDF 0.2 MB)
2017
Below is the disclosure information for Luxembourg in English as per EFPIA regulations. In case of questions please contact us.
2019
-
Novartis
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.3 MB)
-
Sandoz
2018
-
Novartis
Disclosure Report (PDF 0.3 MB) Methodological Note (PDF 0.6 MB)
-
Alcon
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.6 MB)
-
Sandoz
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.6 MB)
2017
Below is the disclosure information for Malta in English as per EFPIA regulations. In case of questions please contact us.
2019
-
Novartis
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.2 MB)
-
Sandoz
2018
-
Novartis
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.2 MB)
-
Sandoz
2017
Disclosure Report
Below is the disclosure information for North Macedonia in English as per EFPIA regulations. In case of questions please contact us.
2019
Disclosure Report
Disclosure Report
Disclosure Report
Disclosure Report
U prilogu se nalaze informacije koje će biti objavljene za Srbiju, na srpskom jeziku, po regulativi EFPIE. U slučaju bilo kakvih pitanja budite slobodni da nas kontaktirate.
2019
-
Novartis
Disclosure Report (PDF 0.7 MB) Methodological Note (PDF 0.6 MB)
-
Sandoz
Disclosure Report (PDF 1.2 MB) Methodological Note (PDF 0.5 MB)
2018
-
Novartis
Disclosure Report (PDF 0.4 MB) Methodological Note (PDF 0.6 MB)
-
Alcon
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.2 MB)
-
Sandoz
Disclosure Report (PDF 0.8 MB) Methodological Note (PDF 0.6 MB)
2017
Spodaj so glede na zahteve EFPIA v slovenskem jeziku objavljeni podatki o prenosih sredstev. V primeru morebitnih vprašanj nas prosimo kontaktirajte.
2019
-
Novartis
Disclosure Report (PDF 0.3 MB) Methodological Note (PDF 0.5 MB)
-
Sandoz
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 0.5 MB)
2018
-
Novartis
Disclosure Report (PDF 0.3 MB) Methodological Note (PDF 1.0 MB)
-
Alcon
Disclosure Report (PDF 0.1 MB) Methodological Note (PDF 1.0 MB)
-
Sandoz
Disclosure Report (PDF 1.0 MB) Methodological Note (PDF 1.0 MB)
2017
Disclosure Report
Disclosure Report
Disclosure Report
Disclosure Report
EFPIA Codes of Conduct
Understand industry interactions with Healthcare Professionals and Healthcare Organizations.